The APOLLO Phase 3 topline readout is the key catalyst. Investors should monitor the webcast on October 19 for efficacy and safety data; the outcome will determine near-term valuation, as bitopertin is Disc's lead asset.
Price Chart
Executive Summary
Disc Medicine announced a corporate webcast to discuss topline results from the APOLLO Phase 3 trial of bitopertin in erythropoietic protoporphyria (EPP). The results are expected to be disclosed on October 19, 2026, making this a binary catalyst event for the stock.
Key Facts
- Disc Medicine will host a webcast on October 19, 2026 to discuss topline results from the APOLLO Phase 3 trial of bitopertin in EPP.
- Bitopertin is an investigational oral GlyT1 inhibitor designed to modulate heme biosynthesis, with potential to be the first disease-modifying therapy for EPP.
- The APOLLO trial is a double-blind, placebo-controlled Phase 3 study; no results have been disclosed yet.
- Disc Medicine obtained global rights to bitopertin from Roche in May 2021.
Financial Impact
Binary catalyst — positive topline results could drive significant upside (8-15% CAR per early-biotech approval literature), while negative results could lead to substantial downside (20-50% for single-asset biotech). No financial figures disclosed.
Risk Factors
- Negative or mixed topline results could lead to a significant stock decline, especially given Disc's reliance on bitopertin.
- Regulatory and manufacturing risks remain even with positive data.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3382949 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | SC 13D/A | $77.66 | awaiting T+20 | — | $77.66 (+0.00%) |
Oct 22, 2026 4d ago | 8-K | $74.51 | awaiting T+20 | — | $77.66 (−4.23%) |
Oct 21, 2026 5d ago | 424B5 | $75.03 | awaiting T+20 | — | $77.66 (−3.51%) |
Oct 21, 2026 5d ago | 144 | $75.03 | awaiting T+20 | — | $77.66 (+3.51%) |
Oct 21, 2026 5d ago | 144 | $75.03 | awaiting T+20 | — | $77.66 (+3.51%) |
Oct 21, 2026 5d ago | 144 | $75.03 | awaiting T+20 | — | $77.66 (+3.51%) |
Oct 20, 2026 6d ago | 144 | $76.00 | awaiting T+20 | — | $77.66 (+2.18%) |
Oct 20, 2026 6d ago | 144 | $76.00 | awaiting T+20 | — | $77.66 (+2.18%) |
Oct 20, 2026 6d ago | 144 | $76.00 | awaiting T+20 | — | $77.66 (+2.18%) |
Oct 19, 2026 7d ago | 424B5 | $79.48 | awaiting T+20 | — | $77.66 (+2.29%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers